Loading
Velorum Therapeutics
Velorum is developing cancer drugs that exploit heme, the iron-carrying molecule tumours depend on in unusual ways.
Overview
Velorum Therapeutics develops medicines built on the biology of heme, the iron-containing molecule central to oxygen transport and cellular metabolism, on the premise that tumour cells handle heme differently from normal cells and that this can be exploited therapeutically. The company is tagged oncology in the YC directory; its public materials give limited detail on targets or candidates, and work is preclinical. No sourced financing rounds are recorded.
Headquarters
San Francisco, CA, US
Funding
All startupsStartupYC W24
Investors
Type
Stage
Startup · Y Combinator Winter 2024
Website
Connected
4Similar pages
- CompanyAlixia
Shares Y Combinator, Small-molecule kinase inhibitors and the tag yc.
- CompanyAltay Therapeutics
Shares Y Combinator, Small-molecule kinase inhibitors and the tag yc.
- CompanyHarmonic Discovery
Shares Y Combinator, Small-molecule kinase inhibitors and the tag yc.
- CompanyAluna
Shares Y Combinator and the tag yc.
- CompanyMednet (theMednet)
Shares Y Combinator and the tag yc.
- CompanyReverie Labs
Shares Y Combinator, Small-molecule kinase inhibitors and the tag yc.
- CompanyDelee
Shares Y Combinator and the tag yc.
- CompanyResistanceBio (Viosera Therapeutics)
Shares Y Combinator and the tag yc.
fronts
technologies
companies
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
velorumtx.com · 1
ycombinator.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/